黄芪对初诊2型糖尿病患者血清晚期糖基化终末产物、可溶性糖基化终末产物受体水平的影响

目的 观察黄芪对初诊2型糖尿病患者血清晚期糖基化终末产物(AGEs)、可溶性糖基化终末产物受体(sRAGE)水平的影响.方法 选择2010年9月至2011年12月江苏省常熟市中医院(新区医院)内分泌科初诊2型糖尿病患者56例,按随机数字表法分为两组各28例,对照组给予控制血糖、血压、血脂等治疗,治疗组在对照组基础上加用黄芪颗粒剂冲服,两组均治疗12周为1个疗程,治疗前后均检测生化指标,采用酶联免疫吸附法检测血清AGEs、sRAGE水平.结果 ①对照组糖化血红蛋白(HbA1c)、甘油三脂(TG)治疗后[(7.28±0.83)％、(1.45±0.39) mmol/L]较同组治疗前[(9.57±1.14)％、(1.92±1.01) mmol/L]明显下降(t值分别为5.75、2.79,P＜0.05);②治疗组HbA1c、TG治疗后[(7.16±0.88)％、(1.53±0.41) mmol/L]较同组治疗前[(9.29±1.62)％、(2.11±0.79) mmol/L]下降(t值分别为6.08、2.40,P＜0.05);③治疗组治疗后血清sRAGE水平(20.38±8.01) ng/ml较同组治疗前(15.10±9.22) ng/ml升高(t＝-2.29,P＜0.05),与对照组治疗后(15.13±9.27) ng/ml比较,差异有统计学意义(t＝-1.17,P＜0.05).结论 黄芪可上调初诊2型糖尿病患者血清sRAGE表达.

Study on the effect of astragalus on serum AGEs, sRAGE levels with newly diagnosed type 2 diabetic patients

Objective To understand the effect of astragalus on serum levels of advanced glycation end products （AGEs）, soluble receptor for advanced glycation end products （sRAGE） in newly diagnosed patients with type 2 diabetes. Methods 60 patients of newly diagnosed type 2 diabetes were randomly divided into control group （28 patients） and treatment group （28 patients）, the control group was given control of blood glucose, blood pressure, lipids and other necessary treatment, and the treatment group was additionally treated with astragalus granule based on the control group. The course for both treatments is 12 weeks. Various clinical and biochemical parameters were tested before and after treatment in both groups with enzyme-linked immunosorbent assay for the detection of serum AGEs, sRAGE levels. Results （1） Glycosylated hemoglobin （HbAIc） in the control group after treatment （7.28±0.83） % was significantly decreased than before treatment （9.57± 1.14）%, the difference was statistically significant （t=5.75, P〈0.05）; glycerin three greases （TG） in the control group after the treatment （1.45 ± 0.39）mmol/L decreased significantly compared with those before treatment （1.92±1.01）mmol/L, the difference was statistically significant（t=2.79, P〈0.05）; （2） HbAlc （7.16±0.88） % in the treatment group after treatment was significantly decreased than before treatment （9.29± 1.62） %, the difference was statistically significant （t=6.08, P〈0.05） ; TG （1.53 ±0.41）mmol/L in the treatment group after treatment was significantly decreased compared with those before treatment （2.11 ± 0.79）mmol/L, the difference was statistically significant （t= 2.40, P〈0.05）, the levels of serum sRAGE （20.38 ± 8.01） ng/ml in the treatment group after treatment increased obviously compared with those before treatment （15.10±9.22）ng/ml, the difference was statistically significant （t=-2.29, P〈0.05）; 0 The level of serum sRAGE （20.38 ± 8.01）ng/ml in the treatment group after treatment increased obviously than the levels of serum sRAGE （15.13±9.27）ng/ml in the control group after treatment, the difference was statistically significant （t=- 1.17, P〈0.05）. Conclusion Astragali can increase serum sRAGE expression in newly diagnosed type 2 diabetic patients.